Search Results

You are looking at 1 - 10 of 10 items for :

  • "chronic neutropenia" x
Clear All
Full access

Gary H. Lyman and David C. Dale

M yeloid growth factors have been used for more than 20 years to ameliorate myelotoxicity after cancer chemotherapy and to prevent infections in patients with chronic neutropenia. Almost all data on long-term outcomes come from studies of

Full access

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt and Michael Westmoreland

chemotherapy and radiation is not recommended. Severe Chronic Neutropenia These NCCN Guidelines focus on chemotherapy-induced neutropenia in the cancer setting. Severe chronic neutropenia that requires G-CSF therapy is briefly discussed in this section

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer and Maria Ho

autologous bone marrow transplantation or delayed autologous engraftment. 107 , 108 It has also been used for mobilization, but G-CSF use has been favored for this purpose. Severe Chronic Neutropenia These NCCN Guidelines are focused on

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt and Michael K. Wong

healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project . Bone Marrow Transplant 2007 ; 40 : 185 – 192 . 33 Aapro MS Cameron DA

Full access

Andrew D. Zelenetz and Pamela S. Becker

consolidation chemotherapy; patients with cancer undergoing bone marrow transplantation or peripheral blood progenitor cell collection and therapy; patients with severe chronic neutropenia; and patients with HIV infection. “Filgrastim-sndz is interchangeable

Full access

David C. Dale

Hematol 1989 ; 26 : 7 – 14 . 15 Dale DC Bonilla MA Davis MW . A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia . Blood 1993 ; 181 : 2496 – 2502 . 16 Smith TJ

Full access

Olga Frankfurt and Martin S. Tallman

; 11 : 466 – 478 . 3. Lieschke GJ Grail D Hodgson G . Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization . Blood 1994

Full access

Gary H. Lyman

transplant, of nonmyeloid malignancies (eg, acute myeloid leukemia), of severe chronic neutropenia, and for progenitor cell mobilization or collection. Concerns About Biosimilars Beyond data presented to the FDA, biosimilars are subject to variability and

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns and Lenora Pluchino

blood progenitor cell (PBPC) collection and therapy, and patients with severe chronic neutropenia. Filgrastim is also approved by the FDA for the treatment of patients acutely exposed to myelosuppressive doses of radiation. 8 Although the European

Full access

Katy Winckworth-Prejsnar, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C. Lyn Fitzgerald and Robert W. Carlson

consolidation chemotherapy; (3) cancer undergoing bone marrow transplantation or peripheral blood progenitor cell collection and therapy; (4) severe chronic neutropenia; and (5) HIV infection. 24 Although approval of the first biosimilars and numerous